healthcare

cannabis plants

Marijuana Price Ticks Up to $1,705

For the week ended Friday, July 22, the spot price index for a pound of cannabis increased 0.3% from $1,700 in the prior week to $1,705. According to the analysts ...
Read Full Story »
Female patient on gurney

Is This the Turning Point Puma Biotech Investors Have Waited For?

Puma Biotechnology Inc. (NYSE: PBYI) watched its shares make a handy gain on Friday morning after the firm released updated results from its late-stage breast cancer trial. Although 2016 has been ...
Read Full Story »
M&A

Why the Relypsa Merger Is a Great Idea

Relypsa Inc. (NASDAQ: RLYP) made a splash in the markets on Thursday after the company announced an acquisition agreement. Although the biotech and pharma industries have been hit hard in ...
Read Full Story »
Female patient on gurney

Could This Be the Turning Point for Progenics and Valeant?

Shares of Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Valeant Pharmaceuticals International Inc. (NYSE: VRX) made handy gains in the market on Wednesday following a key U.S. Food and Drug Administration (FDA) ...
Read Full Story »
Colorado, Marijuana copy

Marijuana News Roundup: Not All California Pot Growers Favor Proposition 64

Now that the state of California has approved a ballot initiative (called Proposition 64) that would legalize marijuana for recreational use, the state's already-booming marijuana growing industry is split nearly ...
Read Full Story »
cannabis plants

Marijuana Price Tumbles 10% to $1,700

For the week ended Friday, July 15, the spot price index for a pound of cannabis decreased 9.9% from $1,886 in the prior week to $1,700. According to the analysts ...
Read Full Story »
Female patient on gurney

Synergy Pharmaceuticals Sinks on FDA Update

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) stumbled on Friday, and over the course of the week for that matter, despite a strong upward push in the broad markets. The company has ...
Read Full Story »
Pills and tablets

Why the Teva Acquisition Proves It Is a Stock to Own for the Decade

It is no secret that drug price pressure and the winds of political change have been hurting almost every large company tied to the pharmaceutical and biotech industries. Even though ...
Read Full Story »
Prescription drugs

Short Sellers Run for Cover From Major Pharma

The short interest data have been released for the June 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
biotech word cloud

Short Sellers Become More Selective on Major Biotechs

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. In ...
Read Full Story »
Female patient on gurney

CytRx Crumbles on Late-Stage Whiff

CytRx Corp. (NASDAQ: CYTR) absolutely crumbled in Tuesday’s session after the company released less than favorable late-stage results. The company announced the results of an analysis of its global, randomized, ...
Read Full Story »
blue eye

Shire Gains Key FDA Approval in Dry Eye Treatment

Shire PLC (NASDAQ: SHPG) made waves Tuesday morning following a key U.S. Food and Drug Administration (FDA) approval. The company announced that the FDA has approved Xiidra (lifitegrast ophthalmic solution) 5%, ...
Read Full Story »
Doctor, Health (pulse) copy

Protagonist Therapeutics Files for IPO

Protagonist Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing, but the offering ...
Read Full Story »
Pills and tablets

Biotechs With Drug Pipelines Closest to Zero Valuation

As biotech valuations and share price remain muted versus historic trends, investors have been evaluating which of the best biotech companies are offering the most upside. Other investors are looking ...
Read Full Story »
Unhealthy Person

Sage Therapeutics Scores Huge Win in Depression Trial

Sage Therapeutics Inc. (NASDAQ: SAGE) blew out expectations early on Tuesday morning after the company released results from its mid-stage depression trial. The company announced positive top-line results from its ...
Read Full Story »